Compare CF & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CF | NBIX |
|---|---|---|
| Founded | 1946 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.5B |
| IPO Year | 2005 | 1996 |
| Metric | CF | NBIX |
|---|---|---|
| Price | $119.70 | $154.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | $118.93 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | 33.09 | ★ 41.95 |
| EPS | ★ 8.71 | 3.30 |
| Revenue | ★ $7,084,000,000.00 | $161,626,000.00 |
| Revenue This Year | $3.85 | $24.73 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ $13.52 | $46.82 |
| Revenue Growth | 19.34 | ★ 977.51 |
| 52 Week Low | $75.42 | $122.14 |
| 52 Week High | $141.96 | $186.12 |
| Indicator | CF | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 37.64 |
| Support Level | $111.57 | $153.96 |
| Resistance Level | $130.53 | $161.29 |
| Average True Range (ATR) | 4.21 | 6.19 |
| MACD | -0.45 | -1.86 |
| Stochastic Oscillator | 60.12 | 15.14 |
CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.